A research team led by researchers from the University of Kansas and KU Cancer Center has developed a device which could detect cancer in a minuscule amount of blood or blood component.
The device, which is called a “3D nano-patterned chip”, identifies and diagnoses cancer by filtering for exosomes, pushing them to meet the surface of the ship for analysis. Exosomes help in sending messages to the recipient cells and communicating molecular information important in many biological functions. In the case of cancerous cells, these contain biological information that can direct tumor growth and spread in case of cancerous cells.
Basically, tumors send out exosomes packaging active molecules that mirror the biological features of the parental cells. While all cells produce exosomes, tumor cells are active compared to normal cells.
To test the chip’s effectiveness, the researchers used clinical samples from patients suffering from ovarian cancer, a type of cancer that is notoriously hard to …

Symptoms of Tongue Cancer

Tongue cancer is a type of oral cancer that usually develops in the squamous cells which form the surface of the tongue. It develops at the front surface of the tongue, though Cancer can develop in two different areas of the tongue. Cancer developed at the back of the tongue is called oropharyngeal cancer.  Squamous cell carcinoma is the most common type of tongue cancer. The primary symptoms of tongue cancer are a painful tongue and sore on the tongue that does not heal. Other symptoms of tongue cancer include: ·stiff jaw or tongue, ·pain in the jaw or throat, ·a tongue ulcer, ·         a problem in swallowing or chewing food, ·bleeding from the tongue, ·numbness in mouth etc 

The symptoms of tongue cancer are similar to those of other types of oral cancers, therefore, they may not be evident in the early stages of the diseases.

It is possible for people to have some of these symptoms without having the tongue cancer or any other type of oral cancer.

Revlimid slows down smoldering myeloma

A recent clinical trial the study has suggested that the anti-cancer drug Revlimid, also called Lenalidomide, may slow down the progression of smoldering myeloma into multiple myeloma. Revlimid is already used to treat multiple myeloma. The study revealed that individuals who received Revlimid had a reduced risk of developing multiple myeloma with initial 3 years than the individuals who were under the observation of developing the disease for the same period. Myeloma is caused by abnormal growth of plasma cells in the bone marrow. Plasma cells are a type of white blood cells in the bone marrow. Bones, immune system, kidneys, and red blood cell count are get affected by this disease. Smoldering myeloma is a pre-diseased condition in which certain proteins in the blood cause plasma cells to grow abnormally in the bone marrow. Though it does not show any symptoms of disease, however about half of the individuals diagnosed with the condition develop multiple myeloma within 5 years. Explore m…

FDA approval to addition of OS Data in labelling of Gilteritinib

The US Food and Drug Administration has approved the addition of overall survival (OS) data in labelling process of Gilteritinib, a cancer drug which was indicated for adult patients who had relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. FLT3 is a receptor tyrosine kinase with important roles in cell survival and proliferation. It is mutated in one -third of AML patients. Gliteritinib acts as an inhibitor of AXL receptor tyrosine kinase, an enzyme in humans encoded by AXL gene . The AXL gene plays a crucial role in facilitating immune escape and drug resistance by cancer cell, leading to metastatic cancers.According to results, treatment with the FLT3-targeted therapeutic Gilteritinib has shown improved survival for patients with relapsed or refractory acute myeloid leukemia harbouring an FLT3 mutation compared with standard chemotherapy regiments.Get to know more such interesting news about oncology at:…

Basic Concepts of Cancer

Cancer is a group of diseases involving abnormal growth of cells which tend to proliferate in an uncontrolled way and, in cases, to metastasize(spread). It is caused by certain changes to genes, the basic physical unit of inheritance, that control the way cells function, especially how they grow and divide.
Normally, human cells grow and divide to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place. When cancer develops, however, this orderly process breaks down. As cells become more and more abnormal, old or damaged cells survive when they should die, and new cells form when they are not needed. These extra cells can divide without stopping and may form growths called tumors. Cancer can involve any tissue of the body and have many different forms in each body area. Most cancers are named for the type of cell or organ in they start.

Oncology 2019 | November 11-12, 2019 | London, UK

Oncology 2019 welcomes renowned oncologists, radiologists, notable scientists, researchers, academicians, research scholars, industrialists and student delegates in the “26th International Conference on Cancer and Oncology”. The two-days event is scheduled to be held on November 11-12,2019 in London, UK. The event has a sole aim of bringing all dignitaries under one roof to share their exceptional knowledge in cancer research and oncology, exchange their distinctive cognizance in this field and promoting cutting edge research and health awareness in combating this deadly disease. This event is centralised to focus on the following sessions: Opportunities in cancer biology research Cancer biomarkers Cancer epigenetics and oncogenomics Robotic oncology and several others
Explore more about oncology with the experts  and share your research work in Oncology 2019